Q-omics provides the consensus-scored ZNF587B profile across patient tissues and cancer cell-line models. ZNF587B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF587B is differentially expressed in 16, with the highest sampling consensus in LIHC. Additionally, ZNF587B RNA expression shows 21,277 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where ZNF587B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF587B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF587B survival associations across molecular data types. ZNF587B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF587B RNA expression–survival associations across cancer types. High ZNF587B expression shows unfavorable associations in KIRP, ACC, LIHC and CESC, but favorable associations in BRCA and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF587B RNA expression.
This table summarizes ZNF587B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF587B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF587B shows higher tumor expression in LIHC, BLCA, STAD, COAD, LUAD and HNSC. The LIHC box plot shows higher ZNF587B RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with ZNF587B in patient tissues and cancer cell lines. In patient samples, ZNF587B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF587B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
